We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-8.50 | -0.48% | 1,775.00 | 1,771.00 | 1,771.50 | 1,779.00 | 1,764.50 | 1,773.50 | 9,685,415 | 16:35:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.80 | 72.91B |
Date | Subject | Author | Discuss |
---|---|---|---|
25/10/2017 21:42 | Never trust a female CEO... | zorija | |
25/10/2017 21:31 | Basically if you actually listen to the investor call it's all about whether the Dividend would still be paid at the same level if GSK were to buy some Pfizer assets. Analysts asked the same question over and over again trying to get her to say if the dividend would be cut in any circumstances. | romeike | |
25/10/2017 21:24 | GlaxoSmithKline Plc (GSK) Q3 2017 Results - Earnings Call Transcript | philanderer | |
25/10/2017 20:30 | Yanks selling over the pond. | montyhedge | |
25/10/2017 18:29 | -6.5% stateside atm, so nearing £14. Might put in a couple of limit orders for the morning. | essentialinvestor | |
25/10/2017 17:55 | Witty left at the right time. | montyhedge | |
25/10/2017 17:55 | Agree with that article, if they bid, then dividend would suffer. | montyhedge | |
25/10/2017 17:42 | That's a fair point Monty ..but better to judge that when we see where it settles ..I wonder how low that will be :) | badtime | |
25/10/2017 17:40 | According to BBC.. Ms Walmsley's immediate priority is the launch of three new products. A shingles vaccine and a three-in-one lung drug have already won US regulatory approval, and the third, a dual-drug regimen for HIV, could get approval by the beginning of December. | philanderer | |
25/10/2017 17:29 | Even better tomorrow morning , still tumbling stateside. | philanderer | |
25/10/2017 16:59 | brexit and interest rates. Great opportunity to buy. | romeike | |
25/10/2017 16:57 | Very happy to be able to add more at 1425p and hopefully more still if it goes lower. | warranty | |
25/10/2017 15:44 | Wow ones years dividend gone down the drain in one day, from capital loss. Thats why I don't invest solely for dividend alone. | montyhedge | |
25/10/2017 15:42 | EI...aye and it's what imho will drag these lower still | badtime | |
25/10/2017 15:37 | US markets look a tad tippy to me. NY, surprised to see you buying with your bearish take on markets. | essentialinvestor | |
25/10/2017 15:30 | Yes, sold about 1/3 around May got just over 1600 for them which was disappointing as they then went up but looks better now of course. Am underwater in these on today's action, though if you include the dividends I think the overall return is up. I tend to buy and hold rather than trade, I have never taken money out of my ISA. | dr biotech | |
25/10/2017 15:17 | Dr Biotech are you still holding your GSK shares. | spcecks | |
25/10/2017 15:16 | They are going need additional action on the cost base imv. Every report Emma has presented so far, the share price has sold off. | essentialinvestor | |
25/10/2017 15:14 | Drop today seems to be more on strategic outlook and currency movement as much as the results. There are a lot of big divi players languishing near yearly lows BT, CNA, NG etc. I've opened some positions in those recently hoping for a longer term income. If I can get a 5% return with the income increasing with inflation it would give me a liveable income. Not that I want to retire just yet | dr biotech | |
25/10/2017 15:11 | Had to top up at 5% down on the day.A new year low,and over reaction,and oversold IMHO. | garycook | |
25/10/2017 15:07 | And Monty returns ..no surprise there :) | badtime |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions